• Integrated Solutions to Maintain Program Compliance

    There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance.   Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses.   CompliancePlus Streamlines workflow, quickly indemnifies… Read more »

  • Stay Ahead of the Game at NACHC’s P&I 2018!

    March 14-17, RxStrategies team members Rhodie Smith and Justin Rolling will be in Washington, D.C. for the National Association of Community Health Centers’ (NACHC) 2018 Policy and Issues Forum. Here, industry leaders will gather to offer unique insight to Members of Congress while offering solutions to current program regulations and legislative issues. Stay ahead of… Read more »

  • Clinical Insights: February 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Biktarvy® (bictegravir, emtricitabine and tenofovir alafenamide) – February 7, 2018 – Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy®… Read more »

  • Make Your Appointment Now!

    The 340B Coalition Winter Conference in San Diego, California is coming up in exactly two weeks! Don’t forget to make your appointment with our team at RxStrategies to discuss solutions to support program compliance and view our 340B CompliancePlus Demo or Dashboard Analytics Demo. Schedule a demo for the conference » Visit Booth #227/326 at… Read more »

  • Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »

  • Clinical Insights: January 22, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval BalcoltraTM (levonorgestrel and ethinyl estradiol and ferrous bisglycinate) – January 19, 2018 – Avion Pharmaceuticals, LLC, received approval of its new drug application (NDA) for the oral contraceptive… Read more »

  • Clinical Insights: January 15, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval No new updates.   New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration… Read more »

  • Join Us at the 340B Coalition Winter Conference!

    Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues… Read more »

  • Maintain 340B Program Compliance in 2018

    RxStrategies works with Covered Entities to provide an integrated approach to streamline the delivery of quality care, while maximizing savings and meeting the regulatory challenges associated with 340B program management. RxStrategies’ 340B solutions are key to a comprehensive and compliant 340B program.  RxStrategies’ CompliancePlus Audit Solution (Self-Audit Portal) Implement internal processes, controls and protocols that… Read more »